The 26S proteasome degrades the majority of cellular proteins and affects all aspects of cellular life. Therefore, the 26S proteasome abundance, proper assembly, and activity in different life contexts need to be precisely controlled. Impaired proteasome activity is considered a causative factor in several serious disorders. Recent advances in proteasome biology have revealed that the proteasome can be activated by different factors or small molecules. Thus, activated ubiquitin-dependent proteasome degradation has effects such as extending the lifespan in different models, preventing the accumulation of protein aggregates, and reducing their negative impact on cells. Increased 26S proteasome-mediated degradation reduces proteotoxic stress and can potentially improve the efficacy of engineered degraders, such as PROTACs, particularly in situations characterized by proteasome malfunction. Here, emerging ideas and recent insights into the pharmacological activation of the proteasome at the transcriptional and posttranslational levels are summarized.

Department of Genetics and Microbiology Charles University and Research Center BIOCEV Pru°myslová 595 Vestec 252 50 Czech Republic

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo náměstí 2 16610 Prague Czech Republic

Zobrazit více v PubMed

Hetz C.; Glimcher L. H. Protein homeostasis networks in physiology and disease. Curr. Opin. Cell Biol. 2011, 23 (2), 123–125. 10.1016/j.ceb.2011.01.004. PubMed DOI PMC

Hipp M. S.; Kasturi P.; Hartl F. U. The proteostasis network and its decline in ageing. Nat. Rev. Mol. Cell Biol. 2019, 20 (7), 421–435. 10.1038/s41580-019-0101-y. PubMed DOI

Ji C. H.; Kwon Y. T. Crosstalk and Interplay between the Ubiquitin–Proteasome System and Autophagy. Molecules Cells 2017, 40 (7), 441–449. 10.14348/molcells.2017.0115. PubMed DOI PMC

Collins G. A.; Goldberg A. L. The Logic of the 26S Proteasome. Cell 2017, 169 (5), 792–806. 10.1016/j.cell.2017.04.023. PubMed DOI PMC

Huang X.; Dixit V. M. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016, 26 (4), 484–498. 10.1038/cr.2016.31. PubMed DOI PMC

Thibaudeau T. A.; Anderson R. T.; Smith D. M. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat. Commun. 2018, 9 (1), 1097.10.1038/s41467-018-03509-0. PubMed DOI PMC

Dörrbaum A. R.; Kochen L.; Langer J. D.; Schuman E. M. Local and global influences on protein turnover in neurons and glia. eLife 2018, 7, e3420210.7554/eLife.34202. PubMed DOI PMC

McShane E.; Sin C.; Zauber H.; Wells J. N.; Donnelly N.; Wang X.; Hou J.; Chen W.; Storchova Z.; Marsh J. A.; Valleriani A.; Selbach M. Kinetic Analysis of Protein Stability Reveals Age-Dependent Degradation. Cell 2016, 167 (3), 803–815.e21. 10.1016/j.cell.2016.09.015. PubMed DOI

Rolfs Z.; Frey B. L.; Shi X.; Kawai Y.; Smith L. M.; Welham N. V. An atlas of protein turnover rates in mouse tissues. Nat. Commun. 2021, 12 (1), 6778.10.1038/s41467-021-26842-3. PubMed DOI PMC

Komander D.; Rape M. The ubiquitin code. Annu. Rev. Biochem. 2012, 81, 203–229. 10.1146/annurev-biochem-060310-170328. PubMed DOI

Weissman A. M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2001, 2 (3), 169–178. 10.1038/35056563. PubMed DOI

Akutsu M.; Dikic I.; Bremm A. Ubiquitin chain diversity at a glance. J. Cell Sci. 2016, 129 (5), 875–880. 10.1242/jcs.183954. PubMed DOI

Pickart C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70, 503–533. 10.1146/annurev.biochem.70.1.503. PubMed DOI

Zheng N.; Shabek N. Ubiquitin Ligases: Structure, Function, and Regulation. Annu. Rev. Biochem. 2017, 86, 129–157. 10.1146/annurev-biochem-060815-014922. PubMed DOI

Voges D.; Zwickl P.; Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 1999, 68, 1015–1068. 10.1146/annurev.biochem.68.1.1015. PubMed DOI

Bard J. A. M.; Goodall E. A.; Greene E. R.; Jonsson E.; Dong K. C.; Martin A. Structure and Function of the 26S Proteasome. Annu. Rev. Biochem. 2018, 87, 697–724. 10.1146/annurev-biochem-062917-011931. PubMed DOI PMC

Tanaka K. The proteasome: overview of structure and functions.. Proc. Japan Acad. Ser. B, Phys. Biol. Sci. 2009, 85 (1), 12–36. 10.2183/pjab.85.12. PubMed DOI PMC

Tanaka K.; Yoshimura T.; Kumatori A.; Ichihara A.; Ikai A.; Nishigai M.; Kameyama K.; Takagi T. Proteasomes (multiprotease complexes) as 20 S ring-shaped particles in a variety of eukaryotic cells. J. Biol. Chem. 1988, 263 (31), 16209–16217. 10.1016/S0021-9258(18)37580-X. PubMed DOI

Groll M.; Heinemeyer W.; Jäger S.; Ullrich T.; Bochtler M.; Wolf D. H.; Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (20), 10976–10983. 10.1073/pnas.96.20.10976. PubMed DOI PMC

Unno M.; Mizushima T.; Morimoto Y.; Tomisugi Y.; Tanaka K.; Yasuoka N.; Tsukihara T. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure (London, England: 1993) 2002, 10 (5), 609–618. 10.1016/S0969-2126(02)00748-7. PubMed DOI

Groll M.; Bochtler M.; Brandstetter H.; Clausen T.; Huber R. Molecular machines for protein degradation. Chembiochem: Eur. J. Chem. Biol. 2005, 6 (2), 222–256. 10.1002/cbic.200400313. PubMed DOI

Rousseau A.; Bertolotti A. Regulation of proteasome assembly and activity in health and disease. Nat. Rev. Mol. Cell Biol. 2018, 19 (11), 697–712. 10.1038/s41580-018-0040-z. PubMed DOI

Husnjak K.; Elsasser S.; Zhang N.; Chen X.; Randles L.; Shi Y.; Hofmann K.; Walters K. J.; Finley D.; Dikic I. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008, 453 (7194), 481–488. 10.1038/nature06926. PubMed DOI PMC

Shi Y.; Chen X.; Elsasser S.; Stocks B. B.; Tian G.; Lee B. H.; Shi Y.; Zhang N.; de Poot S. A.; Tuebing F.; Sun S.; Vannoy J.; Tarasov S. G.; Engen J. R.; Finley D.; Walters K. J. Rpn1 provides adjacent receptor sites for substrate binding and deubiquitination by the proteasome. Science (New York, N.Y.) 2016, 351 (6275), aad942110.1126/science.aad9421. PubMed DOI PMC

Stadtmueller B. M.; Hill C. P. Proteasome activators. Mol. Cell 2011, 41 (1), 8–19. 10.1016/j.molcel.2010.12.020. PubMed DOI PMC

Lee D.; Takayama S.; Goldberg A. L. ZFAND5/ZNF216 is an activator of the 26S proteasome that stimulates overall protein degradation. Proc. Natl. Acad. Sci. U.S.A. 2018, 115 (41), E9550–E9559. 10.1073/pnas.1809934115. PubMed DOI PMC

Fort P.; Kajava A. V.; Delsuc F.; Coux O. Evolution of proteasome regulators in eukaryotes. Genome Biol. Evolution 2015, 7 (5), 1363–1379. 10.1093/gbe/evv068. PubMed DOI PMC

Sakata E.; Eisele M. R.; Baumeister W. Molecular and cellular dynamics of the 26S proteasome. Biochim. Biophys. Acta (BBA)-Proteins and Proteomics 2021, 1869 (3), 140583.10.1016/j.bbapap.2020.140583. PubMed DOI

Schweitzer A.; Aufderheide A.; Rudack T.; Beck F.; Pfeifer G.; Plitzko J. M.; Sakata E.; Schulten K.; Förster F.; Baumeister W. Structure of the human 26S proteasome at a resolution of 3.9 Å. Proc. Natl. Acad. Sci. U.S.A. 2016, 113 (28), 7816–7821. 10.1073/pnas.1608050113. PubMed DOI PMC

Dong Y.; Zhang S.; Wu Z.; Li X.; Wang W. L.; Zhu Y.; Stoilova-McPhie S.; Lu Y.; Finley D.; Mao Y. Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome. Nature 2019, 565 (7737), 49–55. 10.1038/s41586-018-0736-4. PubMed DOI PMC

Sahu I.; Mali S. M.; Sulkshane P.; Xu C.; Rozenberg A.; Morag R.; Sahoo M. P.; Singh S. K.; Ding Z.; Wang Y.; Day S.; Cong Y.; Kleifeld O.; Brik A.; Glickman M. H. The 20S as a stand-alone proteasome in cells can degrade the ubiquitin tag. Nat. Commun. 2021, 12 (1), 6173.10.1038/s41467-021-26427-0. PubMed DOI PMC

Soh W. T.; Roetschke H. P.; Cormican J. A.; Teo B. F.; Chiam N. C.; Raabe M.; Pflanz R.; Henneberg F.; Becker S.; Chari A.; Liu H.; Urlaub H.; Liepe J.; Mishto M. Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing. Nat. Commun. 2024, 15 (1), 1147.10.1038/s41467-024-45339-3. PubMed DOI PMC

Pepelnjak M.; Rogawski R.; Arkind G.; Leushkin Y.; Fainer I.; Ben-Nissan G.; Picotti P.; Sharon M. Systematic identification of 20S proteasome substrates. Mol. Syst. Biol. 2024, 20 (4), 403–427. 10.1038/s44320-024-00015-y. PubMed DOI PMC

Santos R.; Ursu O.; Gaulton A.; Bento A. P.; Donadi R. S.; Bologa C. G.; Karlsson A.; Al-Lazikani B.; Hersey A.; Oprea T. I.; Overington J. P. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discovery 2017, 16 (1), 19–34. 10.1038/nrd.2016.230. PubMed DOI PMC

Burslem G. M.; Crews C. M. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell 2020, 181 (1), 102–114. 10.1016/j.cell.2019.11.031. PubMed DOI PMC

Leestemaker Y.; de Jong A.; Witting K. F.; Penning R.; Schuurman K.; Rodenko B.; Zaal E. A.; van de Kooij B.; Laufer S.; Heck A. J. R.; Borst J.; Scheper W.; Berkers C. R.; Ovaa H. Proteasome Activation by Small Molecules. Cell Chem. Biol. 2017, 24 (6), 725–736.e7. 10.1016/j.chembiol.2017.05.010. PubMed DOI

An S.; Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 2018, 36, 553–562. 10.1016/j.ebiom.2018.09.005. PubMed DOI PMC

Ishida T.; Ciulli A. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. SLAS Discovery: Advancing Life Sciences R & D 2021, 26 (4), 484–502. 10.1177/2472555220965528. PubMed DOI PMC

Li J.; Purser N.; Liwocha J.; Scott D. C.; Byers H. A.; Steigenberger B.; Hill S.; Tripathi-Giesgen I.; Hinkle T.; Hansen F. M.; Prabu J. R.; Radhakrishnan S. K.; Kirkpatrick D. S.; Reichermeier K. M.; Schulman B. A.; Kleiger G. Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting. Mol. Cell 2024, 84 (7), 1304–1320.e16. 10.1016/j.molcel.2024.01.022. PubMed DOI PMC

Li K.; Crews C. M. PROTACs: past, present and future. Chem. Soc. Rev. 2022, 51 (12), 5214–5236. 10.1039/D2CS00193D. PubMed DOI PMC

Liu Z.; Hu M.; Yang Y.; Du C.; Zhou H.; Liu C.; Chen Y.; Fan L.; Ma H.; Gong Y.; Xie Y. An overview of PROTACs: a promising drug discovery paradigm. Mol. Biomed. 2022, 3 (1), 46.10.1186/s43556-022-00112-0. PubMed DOI PMC

Moreau K.; Coen M.; Zhang A. X.; Pachl F.; Castaldi M. P.; Dahl G.; Boyd H.; Scott C.; Newham P. Proteolysis-targeting chimeras in drug development: A safety perspective. Br. J. Pharmacol. 2020, 177 (8), 1709–1718. 10.1111/bph.15014. PubMed DOI PMC

Cantrill C.; Chaturvedi P.; Rynn C.; Petrig Schaffland J.; Walter I.; Wittwer M. B. Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discovery Today 2020, 25 (6), 969–982. 10.1016/j.drudis.2020.03.012. PubMed DOI

Kawanishi N.; Sugimoto T.; Shibata J.; Nakamura K.; Masutani K.; Ikuta M.; Hirai H. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg. Med. Chem. Lett. 2006, 16 (19), 5122–5126. 10.1016/j.bmcl.2006.07.026. PubMed DOI

Hornberger K. R.; Araujo E. M. V. Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders. J. Med. Chem. 2023, 66 (12), 8281–8287. 10.1021/acs.jmedchem.3c00740. PubMed DOI PMC

Ermondi G.; Garcia-Jimenez D.; Caron G. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery. Molecules (Basel, Switzerland) 2021, 26 (3), 672.10.3390/molecules26030672. PubMed DOI PMC

Pike A.; Williamson B.; Harlfinger S.; Martin S.; McGinnity D. F. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discovery Today 2020, 25 (10), 1793–1800. 10.1016/j.drudis.2020.07.013. PubMed DOI

García Jiménez D.; Rossi Sebastiano M.; Vallaro M.; Mileo V.; Pizzirani D.; Moretti E.; Ermondi G.; Caron G. Designing Soluble PROTACs: Strategies and Preliminary Guidelines. J. Med. Chem. 2022, 65 (19), 12639–12649. 10.1021/acs.jmedchem.2c00201. PubMed DOI PMC

Fischer E. S.; Böhm K.; Lydeard J. R.; Yang H.; Stadler M. B.; Cavadini S.; Nagel J.; Serluca F.; Acker V.; Lingaraju G. M.; Tichkule R. B.; Schebesta M.; Forrester W. C.; Schirle M.; Hassiepen U.; Ottl J.; Hild M.; Beckwith R. E.; Harper J. W.; Jenkins J. L.; Thomä N. H. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014, 512 (7512), 49–53. 10.1038/nature13527. PubMed DOI PMC

Van Molle I.; Thomann A.; Buckley D. L.; So E. C.; Lang S.; Crews C. M.; Ciulli A. Dissecting fragment-based lead discovery at the von Hippel–Lindau protein:hypoxia inducible factor 1α protein–protein interface. Chem. Biol. 2012, 19 (10), 1300–1312. 10.1016/j.chembiol.2012.08.015. PubMed DOI PMC

Buckley D. L.; Van Molle I.; Gareiss P. C.; Tae H. S.; Michel J.; Noblin D. J.; Jorgensen W. L.; Ciulli A.; Crews C. M. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J. Am. Chem. Soc. 2012, 134 (10), 4465–4468. 10.1021/ja209924v. PubMed DOI PMC

Buckley D. L.; Gustafson J. L.; Van Molle I.; Roth A. G.; Tae H. S.; Gareiss P. C.; Jorgensen W. L.; Ciulli A.; Crews C. M. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.. Angew. Chem., Int. Ed. 2012, 51 (46), 11463–11467. 10.1002/anie.201206231. PubMed DOI PMC

Békés M.; Langley D. R.; Crews C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discovery 2022, 21 (3), 181–200. 10.1038/s41573-021-00371-6. PubMed DOI PMC

He S.; Dong G.; Cheng J.; Wu Y.; Sheng C. Strategies for designing proteolysis targeting chimaeras (PROTACs). Med. Res. Rev. 2022, 42 (3), 1280–1342. 10.1002/med.21877. PubMed DOI

Roy M. J.; Winkler S.; Hughes S. J.; Whitworth C.; Galant M.; Farnaby W.; Rumpel K.; Ciulli A. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. ACS Chem. Biol. 2019, 14 (3), 361–368. 10.1021/acschembio.9b00092. PubMed DOI PMC

Nijholt D. A.; De Kimpe L.; Elfrink H. L.; Hoozemans J. J.; Scheper W. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr. Med. Chem. 2011, 18 (16), 2459–2476. 10.2174/092986711795843236. PubMed DOI

Huang Q.; Figueiredo-Pereira M. E. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis: Int. J. Programmed Cell Death 2010, 15 (11), 1292–1311. 10.1007/s10495-010-0466-z. PubMed DOI PMC

Wang X.; Li J.; Zheng H.; Su H.; Powell S. R. Proteasome functional insufficiency in cardiac pathogenesis. Am. J. Physiol., Heart Circulatory Physiol. 2011, 301 (6), H2207–H2219. 10.1152/ajpheart.00714.2011. PubMed DOI PMC

Simonetta K. R.; Taygerly J.; Boyle K.; Basham S. E.; Padovani C.; Lou Y.; Cummins T. J.; Yung S. L.; von Soly S. K.; Kayser F.; Kuriyan J.; Rape M.; Cardozo M.; Gallop M. A.; Bence N. F.; Barsanti P. A.; Saha A. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat. Commun. 2019, 10 (1), 1402.10.1038/s41467-019-09358-9. PubMed DOI PMC

Koizumi S.; Hamazaki J.; Murata S. Transcriptional regulation of the 26S proteasome by Nrf1. Proc. Japan Acad. Ser. B, Phys. Biol. Sci. 2018, 94 (8), 325–336. 10.2183/pjab.94.021. PubMed DOI PMC

Livneh I.; Cohen-Kaplan V.; Cohen-Rosenzweig C.; Avni N.; Ciechanover A. The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Res. 2016, 26 (8), 869–885. 10.1038/cr.2016.86. PubMed DOI PMC

Kapetanou M.; Athanasopoulou S.; Gonos E. S. Transcriptional regulatory networks of the proteasome in mammalian systems. IUBMB Life 2022, 74 (1), 41–52. 10.1002/iub.2586. PubMed DOI

Liu P.; Kerins M. J.; Tian W.; Neupane D.; Zhang D. D.; Ooi A. Differential and overlapping targets of the transcriptional regulators NRF1, NRF2, and NRF3 in human cells. J. Biol. Chem. 2019, 294 (48), 18131–18149. 10.1074/jbc.RA119.009591. PubMed DOI PMC

Ibrahim L.; Mesgarzadeh J.; Xu I.; Powers E. T.; Wiseman R. L.; Bollong M. J. Defining the Functional Targets of Cap’n’collar Transcription Factors NRF1, NRF2, and NRF3. Antioxidants (Basel, Switzerland) 2020, 9 (10), 1025.10.3390/antiox9101025. PubMed DOI PMC

Wang Y.; Snell A.; Dyka F. M.; Colvin E. R.; Ildefonso C.; Ash J. D.; Lobanova E. S. Overexpression of Nfe2l1 increases proteasome activity and delays vision loss in a preclinical model of human blindness. Sci. Adv. 2023, 9 (28), eadd547910.1126/sciadv.add5479. PubMed DOI PMC

Radhakrishnan S. K.; Lee C. S.; Young P.; Beskow A.; Chan J. Y.; Deshaies R. J. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol. Cell 2010, 38 (1), 17–28. 10.1016/j.molcel.2010.02.029. PubMed DOI PMC

Steffen J.; Seeger M.; Koch A.; Krüger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol. Cell 2010, 40 (1), 147–158. 10.1016/j.molcel.2010.09.012. PubMed DOI

Uruno A.; Yamamoto M. The KEAP1-NRF2 System and Neurodegenerative Diseases. Antioxidants Redox Signaling 2023, 38 (13–15), 974–988. 10.1089/ars.2023.0234. PubMed DOI

Liu Y.; Hettinger C. L.; Zhang D.; Rezvani K.; Wang X.; Wang H. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington’s disease. J. Neurochem. 2014, 129 (3), 539–547. 10.1111/jnc.12647. PubMed DOI PMC

Kobayashi A.; Tsukide T.; Miyasaka T.; Morita T.; Mizoroki T.; Saito Y.; Ihara Y.; Takashima A.; Noguchi N.; Fukamizu A.; Hirotsu Y.; Ohtsuji M.; Katsuoka F.; Yamamoto M. Central nervous system-specific deletion of transcription factor Nrf1 causes progressive motor neuronal dysfunction. Genes to cells: devoted to molecular & cellular mechanisms 2011, 16 (6), 692–703. 10.1111/j.1365-2443.2011.01522.x. PubMed DOI

Lee C. S.; Lee C.; Hu T.; Nguyen J. M.; Zhang J.; Martin M. V.; Vawter M. P.; Huang E. J.; Chan J. Y. Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (20), 8408–8413. 10.1073/pnas.1019209108. PubMed DOI PMC

Lee C. S.; Ho D. V.; Chan J. Y. Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice. FEBS J. 2013, 280 (15), 3609–3620. 10.1111/febs.12350. PubMed DOI PMC

Villaescusa J C.; Li B.; Toledo E. M; Rivetti di Val Cervo P.; Yang S.; Stott S. R.; Kaiser K.; Islam S.; Gyllborg D.; Laguna-Goya R.; Landreh M.; Lonnerberg P.; Falk A.; Bergman T.; Barker R. A; Linnarsson S.; Selleri L.; Arenas E. A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson’s disease. EMBO J. 2016, 35 (18), 1963–1978. 10.15252/embj.201593725. PubMed DOI PMC

Nath S. R.; Yu Z.; Gipson T. A.; Marsh G. B.; Yoshidome E.; Robins D. M.; Todi S. V.; Housman D. E.; Lieberman A. P. Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction. J. Clin. Invest. 2018, 128 (8), 3630–3641. 10.1172/JCI99042. PubMed DOI PMC

Chan J. Y.; Kwong M.; Lu R.; Chang J.; Wang B.; Yen T. S.; Kan Y. W. Targeted disruption of the ubiquitous CNC-bZIP transcription factor, Nrf-1, results in anemia and embryonic lethality in mice. EMBO J. 1998, 17 (6), 1779–1787. 10.1093/emboj/17.6.1779. PubMed DOI PMC

Leung L.; Kwong M.; Hou S.; Lee C.; Chan J. Y. Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress. J. Biol. Chem. 2003, 278 (48), 48021–48029. 10.1074/jbc.M308439200. PubMed DOI

Kamber Kaya H. E.; Radhakrishnan S. K. Trash Talk: Mammalian Proteasome Regulation at the Transcriptional Level. Trends Genet.: TIG 2021, 37 (2), 160–173. 10.1016/j.tig.2020.09.005. PubMed DOI PMC

Ruvkun G.; Lehrbach N. Regulation and Functions of the ER-Associated Nrf1 Transcription Factor. Cold Spring Harbor Perspect. Biol. 2023, 15 (1), a04126610.1101/cshperspect.a041266. PubMed DOI PMC

Ward M. A.; Vangala J. R.; Kamber Kaya H. E.; Byers H. A.; Hosseini N.; Diaz A.; Cuervo A. M.; Kaushik S.; Radhakrishnan S. K. Transcription factor Nrf1 regulates proteotoxic stress-induced autophagy. J. Cell Biol. 2024, 223 (6), e20230615010.1083/jcb.202306150. PubMed DOI PMC

Hatanaka A.; Nakada S.; Matsumoto G.; Satoh K.; Aketa I.; Watanabe A.; Hirakawa T.; Tsujita T.; Waku T.; Kobayashi A. The transcription factor NRF1 (NFE2L1) activates aggrephagy by inducing p62 and GABARAPL1 after proteasome inhibition to maintain proteostasis. Sci. Rep. 2023, 13 (1), 14405.10.1038/s41598-023-41492-9. PubMed DOI PMC

Bott L. C.; Badders N. M.; Chen K. L.; Harmison G. G.; Bautista E.; Shih C. C.; Katsuno M.; Sobue G.; Taylor J. P.; Dantuma N. P.; Fischbeck K. H.; Rinaldi C. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Human Mol. Genet. 2016, 25 (10), 1979–1989. 10.1093/hmg/ddw073. PubMed DOI PMC

Cuadrado A.; Nebreda A. R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429 (3), 403–417. 10.1042/BJ20100323. PubMed DOI

Munoz L.; Ammit A. J. Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology 2010, 58 (3), 561–568. 10.1016/j.neuropharm.2009.11.010. PubMed DOI

Yang Y.; Kim S. C.; Yu T.; Yi Y. S.; Rhee M. H.; Sung G. H.; Yoo B. C.; Cho J. Y. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediators Inflammation 2014, 2014, 35237110.1155/2014/352371. PubMed DOI PMC

Zhu X.; Rottkamp C. A.; Boux H.; Takeda A.; Perry G.; Smith M. A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Experimental Neurol. 2000, 59 (10), 880–888. 10.1093/jnen/59.10.880. PubMed DOI

Bendotti C.; Atzori C.; Piva R.; Tortarolo M.; Strong M. J.; DeBiasi S.; Migheli A. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J. Neuropathol. Experimental Neurol. 2004, 63 (2), 113–119. 10.1093/jnen/63.2.113. PubMed DOI

Tortarolo M.; Veglianese P.; Calvaresi N.; Botturi A.; Rossi C.; Giorgini A.; Migheli A.; Bendotti C. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell. Neurosci. 2003, 23 (2), 180–192. 10.1016/S1044-7431(03)00022-8. PubMed DOI

Atzori C.; Ghetti B.; Piva R.; Srinivasan A. N.; Zolo P.; Delisle M. B.; Mirra S. S.; Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Experimental Neurol. 2001, 60 (12), 1190–1197. 10.1093/jnen/60.12.1190. PubMed DOI

Lee S. H.; Park Y.; Yoon S. K.; Yoon J. B. Osmotic stress inhibits proteasome by p38 MAPK-dependent phosphorylation. J. Biol. Chem. 2010, 285 (53), 41280–41289. 10.1074/jbc.M110.182188. PubMed DOI PMC

Huang H.; Wang H.; Figueiredo-Pereira M. E. Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential. Cell Biochem. Biophys. 2013, 67 (1), 55–66. 10.1007/s12013-013-9628-2. PubMed DOI PMC

Kamenetsky M.; Middelhaufe S.; Bank E. M.; Levin L. R.; Buck J.; Steegborn C. Molecular details of cAMP generation in mammalian cells: a tale of two systems. J. Mol. Biol. 2006, 362 (4), 623–639. 10.1016/j.jmb.2006.07.045. PubMed DOI PMC

Goldberg A. L.; Kim H. T.; Lee D.; Collins G. A. Mechanisms That Activate 26S Proteasomes and Enhance Protein Degradation. Biomolecules 2021, 11 (6), 779.10.3390/biom11060779. PubMed DOI PMC

VerPlank J. J. S.; Tyrkalska S. D.; Fleming A.; Rubinsztein D. C.; Goldberg A. L. cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 2020, 117 (25), 14220–14230. 10.1073/pnas.2003277117. PubMed DOI PMC

VerPlank J. J. S.; Lokireddy S.; Zhao J.; Goldberg A. L. 26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 2019, 116 (10), 4228–4237. 10.1073/pnas.1809254116. PubMed DOI PMC

Myeku N.; Clelland C. L.; Emrani S.; Kukushkin N. V.; Yu W. H.; Goldberg A. L.; Duff K. E. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nature medicine 2016, 22 (1), 46–53. 10.1038/nm.4011. PubMed DOI PMC

Lokireddy S.; Kukushkin N. V.; Goldberg A. L. cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc. Natl. Acad. Sci. U.S.A. 2015, 112 (52), E7176–E7185. 10.1073/pnas.1522332112. PubMed DOI PMC

Jarome T. J.; Ferrara N. C.; Kwapis J. L.; Helmstetter F. J. CaMKII regulates proteasome phosphorylation and activity and promotes memory destabilization following retrieval. Neurobiol. Learning Memory 2016, 128, 103–109. 10.1016/j.nlm.2016.01.001. PubMed DOI PMC

Jarome T. J.; Kwapis J. L.; Ruenzel W. L.; Helmstetter F. J. CaMKII, but not protein kinase A, regulates Rpt6 phosphorylation and proteasome activity during the formation of long-term memories. Front. Behav. Neurosci. 2013, 7, 115.10.3389/fnbeh.2013.00115. PubMed DOI PMC

Djakovic S. N.; Schwarz L. A.; Barylko B.; DeMartino G. N.; Patrick G. N. Regulation of the proteasome by neuronal activity and calcium/calmodulin-dependent protein kinase II. J. Biol. Chem. 2009, 284 (39), 26655–26665. 10.1074/jbc.M109.021956. PubMed DOI PMC

Kemp B. E.; Pearson R. B. Protein kinase recognition sequence motifs. Trends Biochem. Sci. 1990, 15 (9), 342–346. 10.1016/0968-0004(90)90073-K. PubMed DOI

Makhinson M.; Chotiner J. K.; Watson J. B.; O’Dell T. J. Adenylyl cyclase activation modulates activity-dependent changes in synaptic strength and Ca2+/calmodulin-dependent kinase II autophosphorylation. J. Neurosci: Official Journal of the Society for Neuroscience 1999, 19 (7), 2500–2510. 10.1523/JNEUROSCI.19-07-02500.1999. PubMed DOI PMC

Valverde R. H.; Tortelote G. G.; Lemos T.; Mintz E.; Vieyra A. Ca2+/calmodulin-dependent protein kinase II is an essential mediator in the coordinated regulation of electrocyte Ca2+-ATPase by calmodulin and protein kinase A. J. Biol. Chem. 2005, 280 (34), 30611–30618. 10.1074/jbc.M501880200. PubMed DOI

Zhang F.; Hu Y.; Huang P.; Toleman C. A.; Paterson A. J.; Kudlow J. E. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem. 2007, 282 (31), 22460–22471. 10.1074/jbc.M702439200. PubMed DOI

Yang L.; Parajuli N.; Wu P.; Liu J.; Wang X. S14-Phosphorylated RPN6Mediates Proteasome Activation by PKA and Alleviates Proteinopathy. Circulation Res. 2023, 133 (7), 572–587. 10.1161/CIRCRESAHA.123.322887. PubMed DOI PMC

Hoffman N. J.; Parker B. L.; Chaudhuri R.; Fisher-Wellman K. H.; Kleinert M.; Humphrey S. J.; Yang P.; Holliday M.; Trefely S.; Fazakerley D. J.; Stöckli J.; Burchfield J. G.; Jensen T. E.; Jothi R.; Kiens B.; Wojtaszewski J. F.; Richter E. A.; James D. E. Global Phosphoproteomic Analysis of Human Skeletal Muscle Reveals a Network of Exercise-Regulated Kinases and AMPK Substrates. Cell Metab. 2015, 22 (5), 922–935. 10.1016/j.cmet.2015.09.001. PubMed DOI PMC

Zhang F.; Hu Y.; Huang P.; Toleman C. A.; Paterson A. J.; Kudlow J. E. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem. 2007, 282 (31), 22460–22471. 10.1074/jbc.M702439200. PubMed DOI

Rousseau A.; Bertolotti A. An evolutionarily conserved pathway controls proteasome homeostasis. Nature 2016, 536 (7615), 184–189. 10.1038/nature18943. PubMed DOI PMC

Cohen-Kaplan V.; Ciechanover A.; Livneh I. Stress-induced polyubiquitination of proteasomal ubiquitin receptors targets the proteolytic complex for autophagic degradation. Autophagy 2017, 13 (4), 759–760. 10.1080/15548627.2016.1278327. PubMed DOI PMC

Zhao J.; Zhai B.; Gygi S. P.; Goldberg A. L. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc. Natl. Acad. Sci. U.S.A. 2015, 112 (52), 15790–15797. 10.1073/pnas.1521919112. PubMed DOI PMC

Cohen S.; Nathan J. A.; Goldberg A. L. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discovery 2015, 14 (1), 58–74. 10.1038/nrd4467. PubMed DOI

Sandri M.; Sandri C.; Gilbert A.; Skurk C.; Calabria E.; Picard A.; Walsh K.; Schiaffino S.; Lecker S. H.; Goldberg A. L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117 (3), 399–412. 10.1016/S0092-8674(04)00400-3. PubMed DOI PMC

Zhao J.; Brault J. J.; Schild A.; Cao P.; Sandri M.; Schiaffino S.; Lecker S. H.; Goldberg A. L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metabolism 2007, 6 (6), 472–483. 10.1016/j.cmet.2007.11.004. PubMed DOI

Schlossmann J.; Feil R.; Hofmann F. Signaling through NO and cGMP-dependent protein kinases. Ann. Med. 2003, 35 (1), 21–27. 10.1080/07853890310004093. PubMed DOI

Buglioni A.; Burnett J. C. Jr. New Pharmacological Strategies to Increase cGMP. Annu. Rev. Med. 2016, 67, 229–243. 10.1146/annurev-med-052914-091923. PubMed DOI

Francis S. H.; Busch J. L.; Corbin J. D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62 (3), 525–563. 10.1124/pr.110.002907. PubMed DOI PMC

Wunder F.; Tersteegen A.; Rebmann A.; Erb C.; Fahrig T.; Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 2005, 68 (6), 1775–1781. 10.1124/mol.105.017608. PubMed DOI

Samidurai A.; Xi L.; Das A.; Kukreja R. C. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. Annu. Rev. Pharmacol. Toxicol. 2023, 63, 585–615. 10.1146/annurev-pharmtox-040122-034745. PubMed DOI

Stasch J. P.; Evgenov O. V. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handbook Experimental Pharmacol. 2013, 218, 279–313. 10.1007/978-3-642-38664-0_12. PubMed DOI

VerPlank J. J. S.; Gawron J.; Silvestri N. J.; Feltri M. L.; Wrabetz L.; Goldberg A. L. Raising cGMP restores proteasome function and myelination in mice with a proteotoxic neuropathy. Brain: a journal of neurology 2022, 145 (1), 168–178. 10.1093/brain/awab249. PubMed DOI PMC

Ranek M. J.; Terpstra E. J.; Li J.; Kass D. A.; Wang X. Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 2013, 128 (4), 365–376. 10.1161/CIRCULATIONAHA.113.001971. PubMed DOI PMC

Zhang H.; Pan B.; Wu P.; Parajuli N.; Rekhter M. D.; Goldberg A. L.; Wang X. PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy. Sci. Adv. 2019, 5 (5), eaaw587010.1126/sciadv.aaw5870. PubMed DOI PMC

de Poot S. A. H.; Tian G.; Finley D. Meddling with Fate: The Proteasomal Deubiquitinating Enzymes. J. Mol. Biol. 2017, 429 (22), 3525–3545. 10.1016/j.jmb.2017.09.015. PubMed DOI PMC

Leggett D. S.; Hanna J.; Borodovsky A.; Crosas B.; Schmidt M.; Baker R. T.; Walz T.; Ploegh H.; Finley D. Multiple associated proteins regulate proteasome structure and function. Mol. Cell 2002, 10 (3), 495–507. 10.1016/S1097-2765(02)00638-X. PubMed DOI

Verma R.; Aravind L.; Oania R.; McDonald W. H.; Yates J. R. 3rd; Koonin E. V.; Deshaies R. J. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science (New York, N.Y.) 2002, 298 (5593), 611–615. 10.1126/science.1075898. PubMed DOI

Schnell H. M.; Hanna J. DUB-le vision: snapshots of the proteasome during substrate processing. Trends Biochem. Sci. 2022, 47 (11), 903–905. 10.1016/j.tibs.2022.07.007. PubMed DOI PMC

Zhang S.; Zou S.; Yin D.; Zhao L.; Finley D.; Wu Z.; Mao Y. USP14-regulated allostery of the human proteasome by time-resolved cryo-EM. Nature 2022, 605 (7910), 567–574. 10.1038/s41586-022-04671-8. PubMed DOI PMC

Lee M. J.; Lee B. H.; Hanna J.; King R. W.; Finley D. Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol. Cell. Proteomics: MCP 2011, 10 (5), R110.00387110.1074/mcp.R110.003871. PubMed DOI PMC

Hu M.; Li P.; Song L.; Jeffrey P. D.; Chenova T. A.; Wilkinson K. D.; Cohen R. E.; Shi Y. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 2005, 24 (21), 3747–3756. 10.1038/sj.emboj.7600832. PubMed DOI PMC

Lee B. H.; Lee M. J.; Park S.; Oh D. C.; Elsasser S.; Chen P. C.; Gartner C.; Dimova N.; Hanna J.; Gygi S. P.; Wilson S. M.; King R. W.; Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467 (7312), 179–184. 10.1038/nature09299. PubMed DOI PMC

Hanna J.; Hathaway N. A.; Tone Y.; Crosas B.; Elsasser S.; Kirkpatrick D. S.; Leggett D. S.; Gygi S. P.; King R. W.; Finley D. Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell 2006, 127 (1), 99–111. 10.1016/j.cell.2006.07.038. PubMed DOI

Lee B. H.; Lee M. J.; Park S.; Oh D. C.; Elsasser S.; Chen P. C.; Gartner C.; Dimova N.; Hanna J.; Gygi S. P.; Wilson S. M.; King R. W.; Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467 (7312), 179–184. 10.1038/nature09299. PubMed DOI PMC

Bashore C.; Dambacher C. M.; Goodall E. A.; Matyskiela M. E.; Lander G. C.; Martin A. Ubp6 deubiquitinase controls conformational dynamics and substrate degradation of the 26S proteasome. Nat. Struct. Mol. Biol. 2015, 22 (9), 712–719. 10.1038/nsmb.3075. PubMed DOI PMC

Leggett D. S.; Hanna J.; Borodovsky A.; Crosas B.; Schmidt M.; Baker R. T.; Walz T.; Ploegh H.; Finley D. Multiple associated proteins regulate proteasome structure and function. Mol. Cell 2002, 10 (3), 495–507. 10.1016/S1097-2765(02)00638-X. PubMed DOI

Moon S.; Muniyappan S.; Lee S. B.; Lee B. H. Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases. Int. J. Mol. Sci. 2021, 22 (12), 6213.10.3390/ijms22126213. PubMed DOI PMC

Boselli M.; Lee B. H.; Robert J.; Prado M. A.; Min S. W.; Cheng C.; Silva M. C.; Seong C.; Elsasser S.; Hatle K. M.; Gahman T. C.; Gygi S. P.; Haggarty S. J.; Gan L.; King R. W.; Finley D. An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. J. Biol. Chem. 2017, 292 (47), 19209–19225. 10.1074/jbc.M117.815126. PubMed DOI PMC

McKinnon C.; Goold R.; Andre R.; Devoy A.; Ortega Z.; Moonga J.; Linehan J. M.; Brandner S.; Lucas J. J.; Collinge J.; Tabrizi S. J. Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. Acta Neuropathologica 2016, 131 (3), 411–425. 10.1007/s00401-015-1508-y. PubMed DOI PMC

Homma T.; Ishibashi D.; Nakagaki T.; Fuse T.; Mori T.; Satoh K.; Atarashi R.; Nishida N. Ubiquitin-specific protease 14 modulates degradation of cellular prion protein. Sci. Rep. 2015, 5, 1102810.1038/srep11028. PubMed DOI PMC

Doeppner T. R.; Doehring M.; Bretschneider E.; Zechariah A.; Kaltwasser B.; Müller B.; Koch J. C.; Bähr M.; Hermann D. M.; Michel U. MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. Acta Neuropathologica 2013, 126 (2), 251–265. 10.1007/s00401-013-1142-5. PubMed DOI

Xu D.; Shan B.; Lee B. H.; Zhu K.; Zhang T.; Sun H.; Liu M.; Shi L.; Liang W.; Qian L.; Xiao J.; Wang L.; Pan L.; Finley D.; Yuan J. Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system. eLife 2015, 4, e1051010.7554/eLife.10510. PubMed DOI PMC

Chen L.; Zhu G.; Johns E. M.; Yang X. TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14. Nat. Commun. 2018, 9 (1), 1223.10.1038/s41467-018-03499-z. PubMed DOI PMC

VerPlank J. J. S.; Lokireddy S.; Feltri M. L.; Goldberg A. L.; Wrabetz L. Impairment of protein degradation and proteasome function in hereditary neuropathies. Glia 2018, 66 (2), 379–395. 10.1002/glia.23251. PubMed DOI PMC

Min J. W.; Lü L.; Freeling J. L.; Martin D. S.; Wang H. USP14 inhibitor attenuates cerebral ischemia/reperfusion-induced neuronal injury in mice. J, Neurochem. 2017, 140 (5), 826–833. 10.1111/jnc.13941. PubMed DOI PMC

Banerjee C.; Roy M.; Mondal R.; Chakraborty J. USP14 as a Therapeutic Target Against Neurodegeneration: A Rat Brain Perspective. Front. Cell. Dev. Biol. 2020, 8, 727.10.3389/fcell.2020.00727. PubMed DOI PMC

D’Arcy P.; Brnjic S.; Olofsson M. H.; Fryknäs M.; Lindsten K.; De Cesare M.; Perego P.; Sadeghi B.; Hassan M.; Larsson R.; Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 2011, 17 (12), 1636–1640. 10.1038/nm.2536. PubMed DOI

Tian Z.; D’Arcy P.; Wang X.; Ray A.; Tai Y. T.; Hu Y.; Carrasco R. D.; Richardson P.; Linder S.; Chauhan D.; Anderson K. C. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014, 123 (5), 706–716. 10.1182/blood-2013-05-500033. PubMed DOI PMC

Wang X.; Mazurkiewicz M.; Hillert E. K.; Olofsson M. H.; Pierrou S.; Hillertz P.; Gullbo J.; Selvaraju K.; Paulus A.; Akhtar S.; Bossler F.; Khan A. C.; Linder S.; D’Arcy P. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci. Rep. 2016, 6, 2697910.1038/srep26979. PubMed DOI PMC

Kim E.; Park S.; Lee J. H.; Mun J. Y.; Choi W. H.; Yun Y.; Lee J.; Kim J. H.; Kang M. J.; Lee M. J. Dual Function of USP14 Deubiquitinase in Cellular Proteasomal Activity and Autophagic Flux. Cell Rep. 2018, 24 (3), 732–743. 10.1016/j.celrep.2018.06.058. PubMed DOI

Chakraborty J.; von Stockum S.; Marchesan E.; Caicci F.; Ferrari V.; Rakovic A.; Klein C.; Antonini A.; Bubacco L.; Ziviani E. USP14 inhibition corrects an in vivo model of impaired mitophagy. EMBO Mol. Med. 2018, 10 (11), e9014.10.15252/emmm.201809014. PubMed DOI PMC

VerPlank J. J.; Gawron J. M.; Silvestri N. J.; Wrabetz L.; Feltri M. L. Knockout of PA200 improves proteasomal degradation and myelination in a proteotoxic neuropathy. Life Sci. Alliance 2024, 7 (4), e20230234910.26508/lsa.202302349. PubMed DOI PMC

Chondrogianni N.; Petropoulos I.; Franceschi C.; Friguet B.; Gonos E. S. Fibroblast cultures from healthy centenarians have an active proteasome. Experimental Gerontol. 2000, 35 (6–7), 721–728. 10.1016/S0531-5565(00)00137-6. PubMed DOI

Cabreiro F.; Perichon M.; Jatje J.; Malavolta M.; Mocchegiani E.; Friguet B.; Petropoulos I. Zinc supplementation in the elderly subjects: effect on oxidized protein degradation and repair systems in peripheral blood lymphocytes. Experimental Gerontol. 2008, 43 (5), 483–487. 10.1016/j.exger.2007.10.007. PubMed DOI

Medina D. X.; Caccamo A.; Oddo S. Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathology (Zurich, Switzerland) 2011, 21 (2), 140–149. 10.1111/j.1750-3639.2010.00430.x. PubMed DOI PMC

Rodriguez K. A.; Edrey Y. H.; Osmulski P.; Gaczynska M.; Buffenstein R. Altered composition of liver proteasome assemblies contributes to enhanced proteasome activity in the exceptionally long-lived naked mole-rat. PloS one 2012, 7 (5), e3589010.1371/journal.pone.0035890. PubMed DOI PMC

Rodriguez K. A.; Osmulski P. A.; Pierce A.; Weintraub S. T.; Gaczynska M.; Buffenstein R. A cytosolic protein factor from the naked mole-rat activates proteasomes of other species and protects these from inhibition. Biochim. Biophys. Acta 2014, 1842 (11), 2060–2072. 10.1016/j.bbadis.2014.07.005. PubMed DOI PMC

Pérez V. I.; Buffenstein R.; Masamsetti V.; Leonard S.; Salmon A. B.; Mele J.; Andziak B.; Yang T.; Edrey Y.; Friguet B.; Ward W.; Richardson A.; Chaudhuri A. Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat. Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (9), 3059–3064. 10.1073/pnas.0809620106. PubMed DOI PMC

Lehrbach N. J.; Ruvkun G. Endoplasmic reticulum-associated SKN-1A/Nrf1 mediates a cytoplasmic unfolded protein response and promotes longevity. eLife 2019, 8, e4442510.7554/eLife.44425. PubMed DOI PMC

Kruegel U.; Robison B.; Dange T.; Kahlert G.; Delaney J. R.; Kotireddy S.; Tsuchiya M.; Tsuchiyama S.; Murakami C. J.; Schleit J.; Sutphin G.; Carr D.; Tar K.; Dittmar G.; Kaeberlein M.; Kennedy B. K.; Schmidt M. Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae. PLoS Genetics 2011, 7 (9), e100225310.1371/journal.pgen.1002253. PubMed DOI PMC

Kapeta S.; Chondrogianni N.; Gonos E. S. Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J. Biol. Chem. 2010, 285 (11), 8171–8184. 10.1074/jbc.M109.031575. PubMed DOI PMC

Kapetanou M.; Chondrogianni N.; Petrakis S.; Koliakos G.; Gonos E. S. Proteasome activation enhances stemness and lifespan of human mesenchymal stem cells. Free Radical Biol. Med. 2017, 103, 226–235. 10.1016/j.freeradbiomed.2016.12.035. PubMed DOI

Chondrogianni N.; Sakellari M.; Lefaki M.; Papaevgeniou N.; Gonos E. S. Proteasome activation delays aging and in vivo. Free Radical Biol. Med. 2014, 71, 303–320. 10.1016/j.freeradbiomed.2014.03.031. PubMed DOI

Chondrogianni N.; Georgila K.; Kourtis N.; Tavernarakis N.; Gonos Efstathios S. Enhanced proteasome degradation extends Caenorhabditis elegans lifespan and alleviates aggregation-related pathologies. Free Radical Biol. Med. 2014, 75 (Suppl 1), S18.10.1016/j.freeradbiomed.2014.10.632. PubMed DOI

Chondrogianni N.; Gonos E. S. Proteasome function determines cellular homeostasis and the rate of aging. Adv. Experimental Med. Biol. 2010, 694, 38–46. 10.1007/978-1-4419-7002-2_4. PubMed DOI

Anderson R. T.; Bradley T. A.; Smith D. M. Hyperactivation of the proteasome in Caenorhabditis elegans protects against proteotoxic stress and extends lifespan. J. Biol. Chem. 2022, 298 (10), 10241510.1016/j.jbc.2022.102415. PubMed DOI PMC

Papaevgeniou N.; Panagiotidou E.; Filippopoulou K.; Chondrogianni N. Quest for Bioactive Compounds in Our Diet with Anti-Ageing and Anti-Aggregation Properties. Proceedings 2019, 11 (1), 34.10.3390/proceedings2019011034. DOI

Chondrogianni N.; Gonos E. S. Proteasome activation as a novel antiaging strategy. IUBMB Life 2008, 60 (10), 651–655. 10.1002/iub.99. PubMed DOI

Vilchez D.; Morantte I.; Liu Z.; Douglas P. M.; Merkwirth C.; Rodrigues A. P. C.; Manning G.; Dillin A. RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature 2012, 489 (7415), 263–268. 10.1038/nature11315. PubMed DOI

Mayor T.; Sharon M.; Glickman M. H. Tuning the proteasome to brighten the end of the journey. Am. J. Physiol. Cell Physiol. 2016, 311 (5), C793–C804. 10.1152/ajpcell.00198.2016. PubMed DOI PMC

Giżyńska M.; Witkowska J.; Karpowicz P.; Rostankowski R.; Chocron E. S.; Pickering A. M.; Osmulski P.; Gaczynska M.; Jankowska E. Proline- and Arginine-Rich Peptides as Flexible Allosteric Modulators of Human Proteasome Activity. J. Med. Chem. 2019, 62 (1), 359–370. 10.1021/acs.jmedchem.8b01025. PubMed DOI PMC

Kelmer Sacramento E.; Kirkpatrick J. M.; Mazzetto M.; Baumgart M.; Bartolome A.; Di Sanzo S.; Caterino C.; Sanguanini M.; Papaevgeniou N.; Lefaki M.; Childs D.; Bagnoli S.; Terzibasi Tozzini E.; Di Fraia D.; Romanov N.; Sudmant P. H.; Huber W.; Chondrogianni N.; Vendruscolo M.; Cellerino A.; Ori A. Reduced proteasome activity in the aging brain results in ribosome stoichiometry loss and aggregation. Mol. Syst. Biol. 2020, 16 (6), e9596.10.15252/msb.20209596. PubMed DOI PMC

Katsiki M.; Chondrogianni N.; Chinou I.; Rivett A. J.; Gonos E. S. The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. Rejuvenation Res. 2007, 10 (2), 157–172. 10.1089/rej.2006.0513. PubMed DOI

Chondrogianni N.; Tzavelas C.; Pemberton A. J.; Nezis I. P.; Rivett A. J.; Gonos E. S. Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J. Biol. Chem. 2005, 280 (12), 11840–11850. 10.1074/jbc.M413007200. PubMed DOI

Nguyen N. N.; Rana A.; Goldman C.; Moore R.; Tai J.; Hong Y.; Shen J.; Walker D. W.; Hur J. H. Proteasome β5 subunit overexpression improves proteostasis during aging and extends lifespan in Drosophila melanogaster. Sci. Rep. 2019, 9 (1), 3170.10.1038/s41598-019-39508-4. PubMed DOI PMC

Hwang J. S.; Hwang J. S.; Chang I.; Kim S. Age-associated decrease in proteasome content and activities in human dermal fibroblasts: restoration of normal level of proteasome subunits reduces aging markers in fibroblasts from elderly persons. J. Gerontol. Series A, Biol. Sci. Med. Sci. 2007, 62 (5), 490–499. 10.1093/gerona/62.5.490. PubMed DOI

Chocron E. S.; Munkácsy E.; Kim H. S.; Karpowicz P.; Jiang N.; Van Skike C. E.; DeRosa N.; Banh A. Q.; Palavicini J. P.; Wityk P.; Kalinowski L.; Galvan V.; Osmulski P. A.; Jankowska E.; Gaczynska M.; Pickering A. M. Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer’s-like pathology in mouse and fly APP overexpression models. Sci. Adv. 2022, 8 (23), eabk225210.1126/sciadv.abk2252. PubMed DOI PMC

Choi W. H.; de Poot S. A.; Lee J. H.; Kim J. H.; Han D. H.; Kim Y. K.; Finley D.; Lee M. J. Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. Nat. Commun. 2016, 7, 1096310.1038/ncomms10963. PubMed DOI PMC